NEW YORK, NY, USA I 13, 2024 I OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody ...

SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of ...

These toxins provide new tools for precision cancer medicine, bringing us closer to the elusive “magic bullet.” In addition, ...

Unlike the Conjugate pneumococcal vaccine (PCV), the PPSV vaccine is made with the Polysaccharide (sugars) of the pneumococcal bacteria. It is primarily recommended for the age group of 65 and older.

Department of Biomedical Sciences, School of Public Health, University at Albany, SUNY, Rensselaer, USA Wadsworth Center, New York State Department of Health, Albany, USA RNA Institute, University at ...

Vaxcyte's shares surged more than 40% to a record high on Tuesday after the vaccine developer said its experimental pneumococcal vaccine showed promising results in an early-stage study, with a safety ...

(NASDAQ:PCVX) released topline results from the Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX ...

the company's 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease. VAX-31 was well tolerated and demonstrated a safety profile at all doses ...

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and ...